These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36148567)

  • 21. Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses.
    Geerts P; Martinez G; Schreiner A
    BMC Psychiatry; 2013 Feb; 13():58. PubMed ID: 23414331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F; Schreiner A; Thomas P; Sherif T
    Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region.
    Tang CT; Chua EC; Chew QH; He YL; Si TM; Chiu HF; Xiang YT; Kato TA; Kanba S; Shinfuku N; Lee MS; Park SC; Park YC; Chong MY; Lin SK; Yang SY; Tripathi A; Avasthi A; Grover S; Kallivayalil RA; Udomratn P; Chee KY; Tanra AJ; Rabbani MG; Javed A; Kathiarachchi S; Waas D; Myint WA; Sartorius N; Tran VC; Nguyen KV; Tan CH; Baldessarini RJ; Sim K
    Asia Pac Psychiatry; 2020 Dec; 12(4):e12393. PubMed ID: 32468725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between discontinuation due to withdrawal of consent and use of long-acting injectable antipsychotics: A meta-analysis of randomized trials for schizophrenia.
    Kishi T; Sakuma K; Okuya M; Iwata N
    J Psychiatr Res; 2021 Jan; 132():144-150. PubMed ID: 33096355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Long-Acting Injectable Paliperidone Palmitate on Clinical and Functional Outcomes in Patients With Schizophrenia Based on Illness Duration.
    Kim S; Kim S; Koh M; Choi G; Kim JJ; Paik IH; Kim SH; Choi YS; Lee Y; Suh J; Takeuchi H; Uchida H; Kim E
    J Clin Psychiatry; 2021 Jan; 82(1):. PubMed ID: 33434958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy.
    Bera R; Offord S; Zubek D; Lau G; Lin J; Karson C
    J Clin Psychopharmacol; 2014 Feb; 34(1):30-5. PubMed ID: 24135840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simulated long-term outcomes of early use of long-acting injectable antipsychotics in early schizophrenia.
    Horvitz-Lennon M; Predmore Z; Orr P; Hanson M; Hillestad R; Durkin M; Kim E; Mattke S
    Early Interv Psychiatry; 2019 Dec; 13(6):1357-1365. PubMed ID: 30548103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects.
    Hofer A; Kemmler G; Eder U; Edlinger M; Hummer M; Fleischhacker WW
    J Clin Psychiatry; 2004 Jul; 65(7):932-9. PubMed ID: 15291682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders.
    Auxilia AM; Buoli M; Caldiroli A; Carnevali GS; Tringali A; Nava R; Clerici M; Capuzzi E
    Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN SCHIZOPHRENIA].
    Teitelbaum A; Kodesh A
    Harefuah; 2019 Jul; 158(7):453-457. PubMed ID: 31339245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-acting Injectable Antipsychotics during the COVID-19 pandemic in schizophrenia: An observational study in a real-world clinical setting.
    Barlati S; Nibbio G; Bianchi F; Gigli EBL; Calzavara-Pinton I; Cerati C; Fiori J; Lisoni J; Deste G; Vita A
    Psychiatry Res; 2022 Nov; 317():114878. PubMed ID: 36206591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-acting atypical antipsychotics in schizophrenia: A systematic review and meta-analyses of effects on functional outcome.
    Olagunju AT; Clark SR; Baune BT
    Aust N Z J Psychiatry; 2019 Jun; 53(6):509-527. PubMed ID: 30957510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia.
    Potkin SG; Preda A
    Expert Opin Pharmacother; 2016; 17(3):395-407. PubMed ID: 26864352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
    Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
    Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Attitude and preferences towards oral and long-acting injectable antipsychotics in patients with psychosis in KwaZulu-Natal, South Africa.
    Roopun KR; Tomita A; Paruk S
    S Afr J Psychiatr; 2020; 26():1509. PubMed ID: 32832130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: A systematic review and meta-analysis of randomized controlled trials.
    Kishi T; Oya K; Iwata N
    Psychiatry Res; 2016 Dec; 246():750-755. PubMed ID: 27863801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.